Clearview C. Diff A is a one-step test for the direct qualitative detection of Clostridium difficile toxin A from fecal samples.

Clearly Different

Clearview C. Diff A uses a patented, innovative technology to provide fast, accurate detection of toxin A associated with diarrhea.

• Fast: test provides results in just 30 minutes
• Easy: simple, single-step procedure
• Reliable: built-in-control ensures accuracy
• Flexible: test is suitable for both single and batch testing

Clearly Better

Early detection with Clearview C. Diff A results in improved efficiencies and better patient care.

• Enables timely and appropriate treatment with antibiotics
• Prevents further spread of C. difficile-associated disease

Clearview C. Diff A Testing Procedure
	Prepare sample using the Clearview Stool Filtration System or a benchtop centrifuge for 10 minutes at 13,500 rpm.
	Add 6 drops/125 µL of filtrate to the sample window.
	Interpret the results after 30 minutes. A blue line in the result window indicates a positive result and a blue line in the control window shows that the test has been performed correctly.

For full instructions for use, see package insert.

About C. difficile

Clostridium difficile is a gram-positive, spore-forming anaerobic bacterium. C. difficile is the leading cause of diarrhea outbreaks or C. difficile-associated disease (CDAD) in hospitals, infirmaries, and elderly care units. CDAD is usually caused by antibiotic or chemotherapy disturbing the normal balance of the gut flora.¹ Virtually any antibiotic is capable of causing the condition and studies have shown reduced antibiotic prescription levels can significantly reduce CDAD cases.² Outbreaks in nosocomial environments are difficult to control since the bacteria produces spores that are difficult to eradicate.²

C. difficile has been identified as the organism responsible for toxin production.³ C. difficile produces two large molecular weight toxins, designated A and B. Toxin A is considered to play a more important role in the etiology of CDAD.⁴ The toxins produce symptoms in CDAD patients, which can range from mild diarrhea to pseudomembranous colitis (PMC). PMC manifests as adherent yellowish-white plaques on the intestinal mucosa. Rapid diagnosis of C. difficile is therefore important in order to treat patients and prevent spread of the disease.²

References

1. Hamm L. Clostridium difficile. Pediatr Pharm. 2000;6(6).
2. McNulty C, Logan M, Donald IP, et al. Successful control of Clostridium difficile in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother. 1997;40:707-711.
3. Larson HE, Honour P, Price AB, Borriello SP. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet. 1978;1:1063-1066.
4. Borriello SP. Host and microbial determinant of the spectrum of Clostridium difficile mediated gastrointestinal disorders. Microecol Ther. 1985;15:231-236.